Form 4: Heidi Henson, Director at Perspective Therapeutics, Acquires Stock Options

Heidi Henson, a director at Perspective Therapeutics, acquired 23,000 stock options on June 20, 2024, exercisable at $10.65 per share.

Summary

• On June 20, 2024, Heidi Henson, a director of Perspective Therapeutics, Inc. (CATX), acquired 23,000 stock options.
• The options have an exercise price of $10.65.
• The options vest fully on the first anniversary of the grant date, June 20, 2024, contingent upon continued service.
• The options expire on June 20, 2034.
• Following the transaction, Henson directly owns 23,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants. The director's acquisition could be seen as a slightly positive signal, but it's not a major event.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may view the director's stock option acquisition as a sign of confidence in the company's future prospects.

Key Dates